Author

Mark E. Reynolds

Observed names: M. Reynolds, Mark E Reynolds, Mark Reynolds

Institution: Controlled Risk Insurance Company (United States)

Observed institutions: Brigham and Women's Hospital, Brooke Army Medical Center, Oklahoma Department of Mental Health and Substance Abuse Services, Madigan Army Medical Center, Harvard University, Defense Health Agency, Walter Reed National Military Medical Center, Massachusetts General Hospital, United States Army, Maine Medical Center, Loxo Oncology at Lilly (United States), Geisinger Wyoming Valley Medical Center, University of Southampton, Controlled Risk Insurance Company (United States), Kaiser Permanente Northern California

ORCID: 0000-0002-1104-3634

Observed ORCID: 0000-0002-1104-3634

OpenAlex ID: A5032304577

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study

2018 · Theodore W Laetsch, Steven G DuBois, et al. · The Lancet Oncology · 570

The Safety of Inpatient Health Care

2023 · David W. Bates, David M. Levine, et al. · New England Journal of Medicine · 488

PDF

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas

2018 · Steven G. DuBois, Theodore W. Laetsch, et al. · Cancer · 138

PDF

Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma

2018 · David S. Ziegler, Marie Wong, et al. · British Journal of Cancer · 117

PDF

Racial and Ethnic Differences in Substance Abuse Treatment Initiation and Engagement

2012 · Andrea Acevedo, Deborah W. Garnick, et al. · Journal of Ethnicity in Substance Abuse · 96

Are Washington Circle performance measures associated with decreased criminal activity following treatment?

2007 · Deborah W. Garnick, Constance M. Horgan, et al. · Journal of Substance Abuse Treatment · 64

PDF

Criminal justice outcomes after engagement in outpatient substance abuse treatment

2013 · Deborah W. Garnick, Constance M. Horgan, et al. · Journal of Substance Abuse Treatment · 55

PDF

A performance measure for continuity of care after detoxification: Relationship with outcomes

2014 · Margaret T. Lee, Constance M. Horgan, et al. · Journal of Substance Abuse Treatment · 49

The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model

2015 · Matthew D. Blunt, Matthew J. Carter, et al. · Blood · 40

PDF

Performance Measures and Racial/Ethnic Disparities in the Treatment of Substance Use Disorders

2015 · Andrea Acevedo, Deborah W. Garnick, et al. · Journal of Studies on Alcohol and Drugs · 39

Concomitant Cranial and Ocular Combat Injuries During Operation Iraqi Freedom

2009 · Raymond I. Cho, Hans E. Bakken, et al. · The Journal of Trauma: Injury, Infection, and Critical Care · 32

The Risks to Patient Safety From Health System Expansions

2018 · Susan Haas, Atul Gawande, et al. · JAMA · 26

The Safety of Outpatient Health Care

2024 · David M. Levine, Ania Syrowatka, et al. · Annals of Internal Medicine · 21

A pediatric phase I study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family.

2017 · Theodore Willis Laetsch, Steven G. DuBois, et al. · Journal of Clinical Oncology · 13

Trend of Incidence of Ocular Injury in Service Members of the U.S. Armed Forces in 2016–2019

2022 · Mark E. Reynolds, Weidong Gu · Ophthalmic Epidemiology · 12

An Examination of Methods for Risk-Adjustment of Rehospitalization Rates

2001 · Michael S. Hendryx, Rebecca Moore, et al. · Mental Health Services Research · 10

Incidence of Optic Neuritis and the Associated Risk of Multiple Sclerosis for Service Members of U.S. Armed Forces

2021 · Weidong Gu, Nathan T Tagg, et al. · Military Medicine · 8

Evaluation and Treatment of Ocular Injuries and Vision-Threatening Conditions in Prolonged Field Care

2017 · Mark E Reynolds, Carl Hoover, et al. · Journal of Special Operations Medicine · 4

A phase II basket study of the oral TRK inhibitor LOXO–101 in adult subjects with NTRK fusion-positive tumors

2016 · A. Drilon, D. Hong, et al. · Annals of Oncology · 4

PDF

A pediatric phase 1 study of LOXO-101, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family.

2016 · Ramamoorthy Nagasubramanian, Steven G. DuBois, et al. · Journal of Clinical Oncology · 4

Incident and recurrent cases of central serous chorioretinopathy, active component, U.S. Armed Forces, 2001-2018.

2019 · Mark E Reynolds, James W Karesh, et al. · PubMed · 3

Absolute and relative morbidity burdens attributable to ocular and vision-related conditions, active component, U.S. Armed Forces, 2018.

2019 · Mark E Reynolds, Valerie F Williams, et al. · PubMed · 2

Editorial: The Department of Defense/Veterans Affairs Vision Center of Excellence.

2019 · Mark E Reynolds · PubMed · 1

Helmet use and brain injury in motorcyclists in Florence, South Carolina.

2010 · Erik Askea, William Naso, et al. · PubMed · 1

Rapid Vision Correction by Special Operations Forces

2017 · Mark E Reynolds · Journal of Special Operations Medicine

Works count: 29

Citation count: 1,797

H-index: 13

I10-index: 16